-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] In recent years, with the increasingly fierce competition in the API market, more and more API companies, including Jiuzhou Pharmaceutical, ProLogis, and Minovar, have transformed into CDM.
CDMO" has become the transformation choice for many API compani.
So, how will these pharmaceutical companies perform in the first half of 2022? Jiuzhou Pharmaceutical: Net profit increased by 669% year-on-year Jiuzhou Pharmaceutical announced on July 21 that the company achieved a total operating income of 951 billion yuan in the first half of the year, a year-on-year increase of 594%, and realized a net profit of 466 million yuan attributable to shareholders of the listed compa.
, a year-on-year increase of 66
The reasons for the increase mainly include: during the reporting period, the company deeply expanded customer pipelines and product pipelines, steadily improved the company's R&D capabilities and product delivery capabilities, and further improved the quality and increment of the CDMO business; the company's other businesses maintained a rapid growth moment.
According to the data, Jiuzhou Pharmaceutical has been deeply engaged in special raw materials for more than ten years, and many varieties have occupied a place in the mark.
Since 2008, the company has entered the CDMO indust.
Relying on the in-depth cooperation with Novartis, the CDMO revenue in 2020 will increase by more than 70% year-on-ye.
The industry believes that with the continuous expansion of large-scale cooperation products and the optimization of the company's own customer and order structure, the production capacity will be released on demand, and the future can be expect.
Puluo Pharmaceuticals: Net profit decreased by 204% year-on-year On the evening of July 27, Puluo Pharmaceuticals released its 2022 semi-annual performance report showing that the company’s operating income in the first half of the year reached 986 billion yuan, an increase of 157% year-on-year; attributable to listed companies Shareholders' net profit reached 437 million yuan, a year-on-year decrease of 20
However, the company's API intermediate business and CDMO business both achieved growth in the first half of the ye.
According to the data, the main business of Puluo Pharmaceuticals covers the R&D, production and sales of API intermediates, contract R&D and production services (CDMO), preparations, as well as import and export tra.
After more than 30 years of development and accumulation, the API intermediates business of Puluo Pharmaceuticals has established its own market competitiveness by virtue of its rich product pipeline and outstanding technical research and development capabiliti.
In the first half of the year, Puluo Pharmaceutical's API intermediate business achieved sales revenue of 548 billion yuan during the reporting period, an increase of 110% over the same period of the previous year, with a gross profit of 616 million yuan and a gross profit margin of 13
At the same time, the CDMO business of Puluo Pharmaceutical has more than 20 years of experience in development and production, and the service content covers pre-clinical, clinical and commercial production projec.
In the first half of the year, its CDMO business achieved operating income of 921 million yuan, a year-on-year increase of 279%, with a gross profit of 378 million yuan and a gross profit margin of 40
Hai Purui: Net profit increased by 402%-628% year-on-ye.
On the evening of July 13, Hai Purui released a performance foreca.
In the first half of the year, it achieved a net profit of 474 million yuan to 542 million yuan, a year-on-year increase of 402%-62
Regarding the reasons for the growth in performance, Hepalink believes that thanks to the company's continuous development of enoxaparin sodium preparations in various regions of the world and the steady growth of API business orders, the company's heparin industry chain business revenue has achieved rapid growth; at the same time, based on the orders in ha.
The further growth of the company's CDMO business, as well as the continuous improvement of the on-time and successful delivery rate, the company's CDMO business revenue has maintained a stable and positive tre.
According to the data, Hepalink is a Chinese pharmaceutical company with global business in the field of heparin sodium preparations and APIs, macromolecular drug CDMOs and innovative drug developme.
The company's main products and services include enoxaparin sodium preparations and heparin sodium APIs, Enoxaparin sodium API, and macromolecular drug CDMO servic.
Minovar: Net profit increased by 570%-789% year-on-ye.
On the evening of July 4, Minovar released the semi-annual performance forecast for 202 In the first half of 2022, it is expected to achieve a net profit of 180 million yuan attributable to owners of the parent company -2 100 million yuan, a year-on-year increase of 570%-78
During the reporting period, the company actively developed the CDMO business and accelerated the upgrading and transformation of the enterprise; at the same time, it actively promoted the development strategy of "integration of intermediates, APIs and preparations" to deepen the vertical integration of the entire industry chain; small nucleic acid business and new crown drug intermediate business The smooth progress has brought new drivers to the company's performance grow.
In recent years, Minovar is transforming from traditional API and intermediate business to CDMO and preparation busine.
As of the end of 2021, the company's 9 projects in the first phase of research and development have all been in different stages of work, and the technology transfer has been gradually completed, and will be commercialized so.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
CDMO" has become the transformation choice for many API compani.
So, how will these pharmaceutical companies perform in the first half of 2022? Jiuzhou Pharmaceutical: Net profit increased by 669% year-on-year Jiuzhou Pharmaceutical announced on July 21 that the company achieved a total operating income of 951 billion yuan in the first half of the year, a year-on-year increase of 594%, and realized a net profit of 466 million yuan attributable to shareholders of the listed compa.
, a year-on-year increase of 66
The reasons for the increase mainly include: during the reporting period, the company deeply expanded customer pipelines and product pipelines, steadily improved the company's R&D capabilities and product delivery capabilities, and further improved the quality and increment of the CDMO business; the company's other businesses maintained a rapid growth moment.
According to the data, Jiuzhou Pharmaceutical has been deeply engaged in special raw materials for more than ten years, and many varieties have occupied a place in the mark.
Since 2008, the company has entered the CDMO indust.
Relying on the in-depth cooperation with Novartis, the CDMO revenue in 2020 will increase by more than 70% year-on-ye.
The industry believes that with the continuous expansion of large-scale cooperation products and the optimization of the company's own customer and order structure, the production capacity will be released on demand, and the future can be expect.
Puluo Pharmaceuticals: Net profit decreased by 204% year-on-year On the evening of July 27, Puluo Pharmaceuticals released its 2022 semi-annual performance report showing that the company’s operating income in the first half of the year reached 986 billion yuan, an increase of 157% year-on-year; attributable to listed companies Shareholders' net profit reached 437 million yuan, a year-on-year decrease of 20
However, the company's API intermediate business and CDMO business both achieved growth in the first half of the ye.
According to the data, the main business of Puluo Pharmaceuticals covers the R&D, production and sales of API intermediates, contract R&D and production services (CDMO), preparations, as well as import and export tra.
After more than 30 years of development and accumulation, the API intermediates business of Puluo Pharmaceuticals has established its own market competitiveness by virtue of its rich product pipeline and outstanding technical research and development capabiliti.
In the first half of the year, Puluo Pharmaceutical's API intermediate business achieved sales revenue of 548 billion yuan during the reporting period, an increase of 110% over the same period of the previous year, with a gross profit of 616 million yuan and a gross profit margin of 13
At the same time, the CDMO business of Puluo Pharmaceutical has more than 20 years of experience in development and production, and the service content covers pre-clinical, clinical and commercial production projec.
In the first half of the year, its CDMO business achieved operating income of 921 million yuan, a year-on-year increase of 279%, with a gross profit of 378 million yuan and a gross profit margin of 40
Hai Purui: Net profit increased by 402%-628% year-on-ye.
On the evening of July 13, Hai Purui released a performance foreca.
In the first half of the year, it achieved a net profit of 474 million yuan to 542 million yuan, a year-on-year increase of 402%-62
Regarding the reasons for the growth in performance, Hepalink believes that thanks to the company's continuous development of enoxaparin sodium preparations in various regions of the world and the steady growth of API business orders, the company's heparin industry chain business revenue has achieved rapid growth; at the same time, based on the orders in ha.
The further growth of the company's CDMO business, as well as the continuous improvement of the on-time and successful delivery rate, the company's CDMO business revenue has maintained a stable and positive tre.
According to the data, Hepalink is a Chinese pharmaceutical company with global business in the field of heparin sodium preparations and APIs, macromolecular drug CDMOs and innovative drug developme.
The company's main products and services include enoxaparin sodium preparations and heparin sodium APIs, Enoxaparin sodium API, and macromolecular drug CDMO servic.
Minovar: Net profit increased by 570%-789% year-on-ye.
On the evening of July 4, Minovar released the semi-annual performance forecast for 202 In the first half of 2022, it is expected to achieve a net profit of 180 million yuan attributable to owners of the parent company -2 100 million yuan, a year-on-year increase of 570%-78
During the reporting period, the company actively developed the CDMO business and accelerated the upgrading and transformation of the enterprise; at the same time, it actively promoted the development strategy of "integration of intermediates, APIs and preparations" to deepen the vertical integration of the entire industry chain; small nucleic acid business and new crown drug intermediate business The smooth progress has brought new drivers to the company's performance grow.
In recent years, Minovar is transforming from traditional API and intermediate business to CDMO and preparation busine.
As of the end of 2021, the company's 9 projects in the first phase of research and development have all been in different stages of work, and the technology transfer has been gradually completed, and will be commercialized so.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
